Biosimilars

Biosimilars

Biosimilar medicines:

We believe that biosimilar medicines represent a significant opportunity for the NHS and patients, and we are working with healthcare professionals and commissioners to help realise their potential and make a positive difference to patients.

Great Britain – Herzuma® (trastuzumab) 150 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL

Northern Ireland – Herzuma® (trastuzumab) 150 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

SPC PIL

Great Britain – Herzuma® (trastuzumab) 420 mg powder for concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

SPC PIL

Northern Ireland – Herzuma® (trastuzumab) 420 mg powder for concentrate for solution for infusion

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

SPC PIL

Truxima® (rituximab) 100 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL

Truxima® (rituximab) 500 mg concentrate for solution for infusion

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL

Pelmeg® (pegfilgrastim) 6 mg solution for injection in pre-filled syringe 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse Events should be reported.  Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

 

SPC PIL
Date of preparation: March 2021 UK-BIOS-2100001

Stay connected

Date of preparation: March 2021 UK-BIOS-2100001